Diagnostic Dilemmas in the Use of BMD Testing
Release Date: April 2010
Expiration Date: April 2012
Estimated Time to Complete this Educational Activity: 1.0 hour(s)
Type of Enduring Material: Internet-Based CE
Method of Physician Participation in the Learning Process: Physician learners will read and analyze the subject matter, conduct additional informal research through related internet searches on the subject matter, and complete a post-test assessment of knowledge and skills gained as a result of the activity.
DISCLAIMER: The views and observations presented in this Continuing Education publication are those of the authors/editors and do not necessarily reflect those of the funders or producers of this publication. Readers are urged to consult current prescribing and clinical practice information in any drug, device or procedure discussed in this publication.
Author/Editor:
Angelo Licata, MD, PhD
Director, Center Space Medicine, Department of Endocrinology, Cleveland Clinic
Disclosure Information:
Speaking/Teaching: Eli Lilly, Novartis, Amgen
Consulting: Merck
No off-label use is discussed in this publication.
Objectives
Upon completion of this issue of Osteoporosis Clinical Updates, you will be able to:
- Describe limitations associated with basing a diagnosis of osteoporosis in men or premenopausal women on WHO criteria
- Explain the role of the Z-score in identifying patients with bone loss
- Discuss the significance of low bone density in premenopausal healthy women
- Cite probable determinants of peak bone mass
- Discuss the appropriate use of bone densitometry in the care of healthy premenopausal patients
Launch Diagnostic Dilemmas in the Use of BMD Testing
Continuing Education
After participating in this activity, the reader has the option of taking a post-test to qualify for continuing education credit for this activity. It is estimated it will take 1.0 hour(s) to complete the reading and take the post-test. Continuing education credit will be available for two years from the date of publication.
The National Osteoporosis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Osteoporosis Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The National Osteoporosis Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
The National Osteoporosis Foundation designates this educational activity for a maximum of 1.0 continuing nursing education credit(s).
Other healthcare providers will also be able to receive a certificate of completion; nurse practitioners and physician assistants may request an AMA PRA Category 1 Credit(s)™ certificate.
If you wish to receive continuing education credit, please click here to access the Continuing Education Application. Print this form and complete offline. Complete the registration form then take the 10-question post test and circle your answers on the CE Reporting Form. Then complete the activity evaluation found at the bottom of the CE Reporting Form. You must complete the Post-Test and CE Reporting Form in order to receive credit.
There is a $10.00 fee for this continuing education activity. Payment may be made by check, VISA or MasterCard. We cannot accept any other forms of payment. Please complete the payment information on the CE Reporting Form.
Once the Continuing Education Application is complete, return it with your payment to NOF at the address indicated on the form. Your continuing education certificate will be emailed to you within 3 weeks of receipt.
Software Requirement: Adobe Acrobat Reader is required to read the text for this continuing education activity.
|
|
Acrobat Reader is required to view PDFs. If you need a free copy of Acrobat Reader you can download it here. |
Editorial Board
The Osteoporosis Clinical Updates Editorial Board is comprised of medical specialists, nonspecialists, and a variety of other healthcare professionals involved in research in and management of osteoporosis.
DISCLOSURE OF COMMERCIAL SUPPORT
It is the policy of the National Osteoporosis Foundation (NOF) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored publications and programs. NOF requires the disclosure of the existence of any significant financial interest or any other relationship the sponsor, Editorial Board or Guest Contributors have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. All authors and contributors to this continuing education activity have disclosed any real or apparent interest that may have direct bearing on the subject matter of this program.
Please be advised that NOF’s accreditation status with ACCME and ANCC does not imply endorsement by NOF, ACCME, or ANCC of any commercial products displayed in conjunction with this activity.
STATEMENT ON OFF-LABEL USE
Please be advised that any publication of the Osteoporosis Clinical Updates that discusses off-label use of any medications or devices will be disclosed to the participant.
EDITORIAL BOARD DISCLOSURES
Editor-in-Chief
Angelo Licata, MD, PhD
Director, Center Space Medicine
Department of Endocrinology
Cleveland Clinic
Disclosures: Speaking/Teaching: Eli Lilly, Novartis, Amgen, Consulting: Merck
Adrienne Berarducci, PhD, ARNP, BC
Associate Professor
University of South Florida and
Azure Medical Group
Disclosure: No relationships to disclose
Carolyn J. Bolognese, RN, CDE
Bethesda Health Research Center
Disclosure: Consulting: Amgen, Merck
Speaking/Teaching: Amgen, Merck
JoAnn Caudill, RT, BD, CDT
Bone Health Program Manager
Redwood / Erickson Retirement Communities
Disclosures: No relationships to disclose
Peggy Doheny, PhD, RN, CNS, ONC
Professor and Adult CNS Program Director
Kent State University College of Nursing
Disclosures: No relationships to disclose
Patricia Graham, MD, PC
Owner, Physical Medicine and Rehabilitation / Integrative Medicine
Disclosures: No relationships to disclose
Craig Langman, MD
Head, Kidney Diseases
Childrens Memorial Hospital
Professor, Feinberg School of Medicine
Northwestern University
Disclosure: No relationships to disclose
Barbara Messinger-Rapport, MD, PhD
Director, Center for Geriatric Medicine of the Medicine Institute
Cleveland Clinic
Disclosure: No relationships to disclose
Paul D. Miller, MD
Distinguished Clinical Professor of Medicine
Colorado Center for Bone Research
Disclosures: Consulting: Warner Chilcott, Baxter, Genentech, Eli Lilly, Merck, Novartis, Amgen, GlaxoSmithKline
Speaking/Teaching: Warner Chilcott, Genentech, Eli Lilly, Merck, Novartis, Amgen
Advisory Committee: Warner Chilcott, Genentech, Eli Lilly, Merck, Novartis, Amgen
Research/Grants: Warner Chilcott, Eli Lilly, Merck, Novartis, Amgen
Jeri Nieves, PhD
Associate Professor of Clinical Epidemiology
Columbia University, Helen Hayes Hospital
Disclosure: Consulting: Merck
Mary Beth O’Connell, PharmD, BCPS
Associate Professor, Wayne State University
Eugene Applebaum College of Pharmacy and Health Sciences
Disclosures: Research Grants: Merck
Carol Sedlak, PhD, RN, CNS, ONC, CNE
Professor & Nurse Educator Program Director
Kent State University College of Nursing
Disclosures: No relationships to disclose
Kathy M. Shipp, PT, MHS, PhD
Assistant Professor, Division of Physical Therapy
Department of Community and Family Medicine
Duke University School of Medicine
Disclosure: Speaking/Teaching: Amgen
Andrea Sikon, MD, FACP, CCD, NCMP
Chair, Department of Internal Medicine
Cleveland Clinic
Disclosure: Stockholder: Amgen, Pfizer
Kelly Trippe, MA
Managing Editor, Osteoporosis Clinical Updates
National Osteoporosis Foundation
Disclosure: No relationships to disclose
Susan Randall, RN, MSN, FNP-BC
Senior Director, Science and Education
National Osteoporosis Foundation
Disclosure: No relationships to disclose
